Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest DiagnosticsMIL:1QDX 52 PB Ratio is 3.14 as of Jul. 22, 2026, which is 20% above its 10-year median of 2.62. GuruFocus rates MIL:1QDX with a GF Score™ of 52/100 and a GF Value™ of €164.35 (Fairly Valued). The stock has 8 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Quest Diagnostics ranks worse than 68.72% on this metric.
Quest Diagnostics Inc stock PB Ratio (=3.12) is close to 10-year high of 3.29.
The historical rank and industry rank for Quest Diagnostics's PB Ratio or its related term are showing as below:
MIL:1QDX'
s PB Ratio Range Over the Past 10 Years
Min: 1.74 Med: 2.62 Max: 3.29
Current: 3.12
During the past 13 years, Quest Diagnostics's highest PB Ratio was 3.29. The lowest was 1.74. And the median was 2.62.
MIL:1QDX's PB Ratio is ranked worse than 68.72% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.99
vs MIL:1QDX: 3.12
During the past 12 months, Quest Diagnostics's average Book Value Per Share Growth Rate was 7.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 7.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 4.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 7.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Quest Diagnostics was 28.10% per year. The lowest was 2.20% per year. And the median was 7.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Quest Diagnostics PB Ratio Related Terms
Quest Diagnostics PB Ratio Historical Data
* Premium members only.
The historical data trend for Quest Diagnostics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Quest Diagnostics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Diagnostics PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Quest Diagnostics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Quest Diagnostics (MIL:1QDX) has a PB Ratio of 3.14 as of Jul. 22, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Quest Diagnostics and its competitors. This is 20% above median its historical median of 2.62. Over the past decade, Quest Diagnostics' PB Ratio has ranged from 1.74 to 3.29. According to the industry distribution chart, Quest Diagnostics ranks #134 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 68.7%.
Is Quest Diagnostics' PB Ratio too high?
Quest Diagnostics' current PB Ratio of 3.14 is 20% above median its 10-year median of 2.62. Over the past 10 years, this metric has ranged from a low of 1.74 to a high of 3.29. The Medical Diagnostics & Research industry median PB Ratio is 1.99. Quest Diagnostics' value of 3.14 is 57.8% above this industry median. Based on the distribution chart, Quest Diagnostics ranks #134 out of 195 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Quest Diagnostics has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Quest Diagnostics' PB Ratio compare to LH and MTD?
According to the Medical Diagnostics & Research industry distribution chart, Quest Diagnostics ranks #134 out of 195 companies for PB Ratio. This places Quest Diagnostics in the lower half of its industry. The industry median PB Ratio is 1.99. Quest Diagnostics' value of 3.14 is 57.8% above this benchmark. Historically, Quest Diagnostics' own PB Ratio has ranged from 1.74 to 3.29 over the past decade. While the company's 10-year median is 2.62 vs. the industry median of 1.99, Quest Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 1.99, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Diagnostics's current PB Ratio of 3.14 is 57.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Quest Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Diagnostics's current PB Ratio is 3.14, which is 20% above median its own 10-year median of 2.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Quest Diagnostics (MIL:1QDX) is currently considered Fairly Valued. The stock's GF Value™ is €164.35, compared to a current price of €180.35 — trading 9.7% above its estimated fair value. The current PB Ratio is 3.14, which is 20% above median its 10-year median of 2.62 and 57.8% above the Medical Diagnostics & Research industry median of 1.99. Quest Diagnostics' overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Quest Diagnostics (MIL:1QDX), the current PB Ratio is 3.14 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Quest Diagnostics (MIL:1QDX) Overvalued in 2026?
Based on GuruFocus' analysis, Quest Diagnostics stock appears to be overvalued.
The current stock price of €180.35 is trading 9.7% above its estimated GF Value™ of €164.35.
GuruFocus considers Quest Diagnostics to be Fairly Valued.
Key valuation signals for MIL:1QDX:
PB Ratio: 3.14 (20% above median its 10-year median of 2.62)
GF Value™: €164.35 vs. price of €180.35 (9.7% above fair value)
Industry Position: 57.8% above the Medical Diagnostics & Research median (#134 of 195)
No single metric tells the full story. See the MIL:1QDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
52GF Score
Get the complete analysis for MIL:1QDX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1QDX has been successfully added to your 
